Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTErAMG 330

George S. Laszlo, Mary E. Beddoe, Colin D. Godwin, Olivia M. Bates, Chelsea J. Gudgeon, Kimberly H. Harrington, and Roland B. Walter

Disclosures: R.B.W. received laboratory research grants and/or clinical trial support from Actinium Pharmaceuticals, Inc., Amgen Inc., Amphivena Therapeutics, Inc., Aptevo Therapeutics, Inc., Covagen AG, and Seattle Genetics, Inc.; has ownership interests with Amphivena Therapeutics, Inc.; and is (or has been) a consultant to Amphivena Therapeutics, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Covagen AG, Emergent Biosolutions, Inc. (now Aptevo Therapeutics, Inc.), Pfizer, Inc., and Seattle Genetics, Inc. The other authors declare no competing financial interests.

Contributions: G.S.L., M.E.B., C.D.G., O.M.B., C.J.G., and K.H.H. performed research and revised the manuscript. R.B.W. designed and supervised the study, performed all data analyses, interpreted data, and wrote the manuscript.